5-(4-溴-3-甲基苯基)-2H-四唑 | 885278-34-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(4-溴-3-甲基苯基)-2H-四唑
• 中文别名: 5-(4-溴-3-甲苯基)-1H四氮唑；2H-四唑,5-(4-溴-3-甲基苯基)-
• 英文名称: 5-(4-bromo-3-methylphenyl)-2H-tetrazole
• 英文别名: 5-(4-Bromo-3-methyl-phenyl)-2H-tetrazole
• CAS: 885278-34-2
• 化学式: C₈H₇BrN₄
• 分子量: 239.074
• InChiKey: VRLFFBPGGMFGMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-溴-3-甲基苯基)-2H-四唑 、 三甲基硅烷化重氮甲烷 以 四氢呋喃 为溶剂， 反应 1.0h， 以61%的产率得到5-(4-bromo-3-methylphenyl)-2-methyl-2H-tetrazole
  参考文献：
  名称：

  INDOLE DERIVATIVES AS CRAC MODULATORS

  摘要：

  公式I的化合物： 或其药用可接受的盐， 其中R1、R2、R3和R4按本文定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道（CRAC）相关疾病的用途。

  公开号：

  US20110071150A1
• 作为产物：
  描述：

  4-溴-3-甲基苯甲腈 在 sodium azide 、 三乙胺盐酸盐 作用下， 以 xylenes 为溶剂， 以92%的产率得到5-(4-溴-3-甲基苯基)-2H-四唑
  参考文献：
  名称：

  INDOLE DERIVATIVES AS CRAC MODULATORS

  摘要：

  公式I的化合物： 或其药用可接受的盐， 其中R1、R2、R3和R4按本文定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与钙释放激活钙通道（CRAC）相关疾病的用途。

  公开号：

  US20110071150A1

文献信息

• MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Miao Zhenwei

  公开号：US20090304629A1

  公开（公告）日：2009-12-10

  The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及I、II或III式化合物，或其药学上可接受的盐、酯或前药： 其中W是取代或未取代的杂环环系。这些化合物能够抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包括上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给予包括本发明的化合物的制药组合物来治疗受试者的HCV感染的方法。
• TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20090035271A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
• TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20090035268A1

  公开（公告）日：2009-02-05

  The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
• US7601709B2
  申请人：——

  公开号：US7601709B2

  公开（公告）日：2009-10-13
• US8124584B2
  申请人：——

  公开号：US8124584B2

  公开（公告）日：2012-02-28